SUDA LTD moves to finalise the acquisition of the NovaMist™ Oro–Mucosal Platform Technology

On 18th December 2012, SUDA LTD (SUDA) signed an Option to acquire the NovaMist™ technology from NovaDel Pharma Inc. (NovaDel).

Following completion of the due diligence process, the SUDA Board gave approval to proceed with the proposed acquisition and the Parties are currently finalising a Sale and Purchase Agreement.

On execution of this Agreement, SUDA will be in a position to release details of the Transaction to the market.